OVERVIEW

Upon the [**REDACTED**], the Board will consist of eight Directors, including two executive Directors, three non-executive Directors and three independent non-executive Directors. The Board is responsible, and has general authority for, the management and operation of the Company. Our Directors are appointed for a term of three years and are eligible for re-election upon expiry of their term of office.

Our senior management is responsible for the day-to-day operations of the Company.

All of the Directors and senior management have met the qualification requirements under the Listing Rules for their respective positions.

BOARD OF DIRECTORS

The following table sets forth certain information regarding the members of our Board.

Name	Age	Position	Date of joining our Group	Date of appointment as a Director	Responsibility	Relationship with other Directors and senior management
Mr. Wang Weibin (王偉斌)	55	Chairman of the Board and non-executive Director	June 21, 2004	January 23, 2019	Responsible for providing guidance on overall strategic planning, corporate governance and business direction of our Group	Mr. Wang is the spouse of Ms. Bian
Ms. Bian Jiao (卞嬌)	37	Executive Director and chief executive officer	October 8, 2014	January 23, 2019	Responsible for strategic business direction, and the comprehensive supervision and management on the business of our Group	Ms. Bian is the spouse of Mr. Wang
Mr. Dong Lei (東磊)	45	Executive Director and executive president	December 1, 2024	May 8, 2025	Responsible for supervision and management on integrated healthcare and eldercare business unit, external affairs and major matters	N/A
Mr. Zhang Jianwei (張建偉)	48	Non-executive Director	July 9, 2021	July 9, 2021	Responsible for providing guidance and suggestions on management and operations of our Group	N/A
Ms. Wang Yu (王雨)	36	Non-executive Director	July 9, 2021	July 9, 2021	Responsible for providing guidance and suggestions on management and operations of our Group	N/A
Dr. Ma Weihua (馬蔚華)	77	Independent non-executive Director	[**REDACTED**]	[**REDACTED**]	Responsible for providing independent advice on the operations and management of our Group	N/A
Dr. Lo Wing Yan William (盧永仁)	65	Independent non-executive Director	[**REDACTED**]	[**REDACTED**]	Responsible for providing independent advice on the operations and management of our Group	N/A
Mr. Yang Mingyuan (楊明遠)	43	Independent non-executive Director	[**REDACTED**]	[**REDACTED**]	Responsible for providing independent advice on the operations and management of our Group	N/A

Executive Directors and non-executive Directors

Mr. Wang Weibin (王偉斌), aged 55, is our founder, the chairman of the Board and non-executive Director. Mr. Wang founded Puxiang Investment in June 2004, and was appointed as a Director and redesignated as a non-executive Director in June 2025. Mr. Wang has been the chairman of the Board since January 2019. Mr. Wang is primarily responsible for providing guidance on overall strategic planning, corporate governance and business direction of our Group.

As a distinguished entrepreneur, Mr. Wang founded Shuangquan Group in January 1996 and has served as its chairman of the board of directors since then. Shuangquan Group is a large-scale investment holding group company incorporated in the PRC and involving in a variety of industries including real estate development, technology, education and financial investments. In September 2006, Mr. Wang founded Shenyu Culture and has served as the chairman of the board of directors since then. Shenyu Culture was primarily engaged in the culture and art industry.

Mr. Wang obtained a doctorate of advanced professional studies degree in applied finance specialization in wealth management from University of Geneva in Geneva, Switzerland in May 2021.

Ms. Bian Jiao (卞嬌), aged 37, is our executive Director and chief executive officer. Ms. Bian joined our Group in October 2014 as a vice president of Puxiang Investment. Ms. Bian was appointed as a Director in January 2019 and was redesignated as an executive Director in June 2025. Ms. Bian has been our Company's chief executive officer since January 2019. Ms. Bian is primarily responsible for strategic business direction, the comprehensive supervision and management on the business of our Group, and the management of our medical institutions.

From November 2020 to November 2024, Ms. Bian served as a director in Puxiang Big Health Industry Co., Ltd. (普祥大健康產業有限公司), a company with limited liability incorporated in the PRC with an intention to explore opportunities in the big health industry in Hainan. It was deregistered in November 2024, in light of the fast-evolving policies in Hainan increasing uncertainties to the original business plan. During the Track Record Period and prior to its deregistration, Puxiang Big Health Industry Co., Ltd. had no substantive operation and was wholly owned by Mr. Wang. From December 2013 to April 2017, Ms. Bian served as a vice president in Shuangquan Holdings, principally responsible for the management of major projects such as corporate asset transactions, and corporate finance matters.

Ms. Bian obtained a master's degree in human resources development (international development) from the University of Manchester in the United Kingdom in November 2012 and graduated from PBC School of Finance, Tsinghua University (清華大學五道口金融學院) majoring in business administration in Beijing, the PRC in June 2023.

Mr. Dong Lei (東磊), aged 45, is our executive Director and executive president. Mr. Dong joined our Company as the executive president of our Company in December 2024, appointed as a Director in May 2025 and redesignated as an executive Director in June 2025. Mr. Dong is primarily responsible for supervision and management on integrated healthcare and eldercare business unit, external affairs and major matters.

Prior to joining our Company, from April 2019 to October 2024, Mr. Dong successively served as a person-in-charge in several business sectors under the subsidiaries of China Life Insurance Group (中國人壽保險集團), a state-owned finance group incorporated in the PRC mainly engaged in the insurance industry. From March 2018 to March 2019, Mr. Dong successively served as a person-in-charge in several business sectors under the subsidiaries of China Taiping Insurance Group Limited (中國太平保險集團有限責任公司), a state-owned finance group incorporated in the PRC mainly engaged in the insurance industry.

Mr. Dong obtained a master's degree in public management from Renmin University of China (中國人民大學) in Beijing, the PRC in January 2010.

Mr. Zhang Jianwei (張建偉), aged 48, is our non-executive Director. Mr. Zhang was appointed as a Director in July 2021 and was redesignated as a non-executive Director in June 2025. Mr. Zhang is primarily responsible for providing guidance and suggestions on management and operations of our Group.

Mr. Zhang has served as the chairman of the board of directors and a general manager in Beijing Shuangquan Real Estate Development, which primarily engaged in the real estate development industry, since January 2008. Mr. Zhang has successively served as a chief of staff, executive director and an executive president in Shuangquan Investment, a company with limited liability incorporated in the PRC primarily engaged in investment and asset management, since October 2001.

Mr. Zhang attended and completed the real estate CEO advanced graduate course at Tsinghua University from October 2008 to December 2009, and the real estate senior management course at the Cheung Kong Graduate School of Business (長江商學院) in April 2010.

Ms. Wang Yu (王雨), aged 36, is our non-executive Director. Ms. Wang was appointed as a Director in July 2021 and was redesignated as a non-executive Director in June 2025. Ms. Wang is primarily responsible for providing guidance and suggestions on management and operations of our Group.

Ms. Wang has served as the legal director in Shuangquan Investment since June 2017. From December 2015 to March 2017, Ms. Wang served as a paralegal in DeHeng Law Offices (Kunming) (北京德恒(昆明)律師事務所).

Ms. Wang obtained her master's degree in international economic law from SOAS, University of London in the United Kingdom in December 2013. Since September 2022, Ms. Wang has been pursuing her doctorate's degree in civil and commercial law at the University of Chinese Academy of Social Sciences (中國社會科學院大學) in Beijing, the PRC, which is expected to be completed in July 2026.

Independent non-executive Directors

Dr. Ma Weihua (馬蔚華), aged 77, was appointed in June 2025 as our independent non-executive Director which will become effective upon the [**REDACTED**]. Dr. Ma is primarily responsible for providing independent advice on the operations and management of our Group.

Dr. Ma has served as an independent non-executive director in various companies listed on the Stock Exchange, including (1) Modern Innovative Digital Technology Company Limited (新質數字科技有限公司) (stock code: 2322), which was previously known as Hong Kong Chaoshang Group Limited (香港潮商集團有限公司), a company primarily engaged in the trading industry, since August 2024; (2) China Gas Goldings Limited (中國燃氣控股有限公司) (stock code: 384), a company primarily engaged in the gas industry, since January 2022 and (3) Haidilao International Holding Ltd. (海底撈國際控股有限公司) (stock code: 6862), a company primarily engaged in the food and beverage industry, since August 2021. Prior to that, Dr. Ma served as an independent non-executive director in Legend Holdings Corporation (聯想控股股份有限公司), a company listed on the Stock Exchange (stock code: 3396), which was primarily engaged in the finance industry, from June 2015 to June 2024, and Bison Finance Group Limited (貝森金融集團有限公司), a company listed on the Stock Exchange (stock code: 888), which was primarily engaged in the finance industry, from November 2017 to September 2023.

In addition, Dr. Ma is the chairman of China Global Philanthropy Institute (深圳國際公益學院) and the director-general of One Foundation (壹基金公益基金會), respectively. From January 1999 to May 2013, Dr. Ma served as the president and chief executive officer of China Merchants Bank Co., Ltd. (招商銀行股份有限公司), a company primarily engaged in the banking industry in the PRC, which was listed on the Stock Exchange (stock code: 3968) and Shanghai Stock Exchange (stock code: 600036).

Dr. Ma obtained his doctorate's degree in economics from the Southwestern University of Finance and Economics (西南財經大學) in Chengdu, the PRC in June 1999.

Dr. Lo Wing Yan William (盧永仁), aged 65, was appointed in June 2025 as our independent non-executive Director which will become effective upon the [**REDACTED**]. Dr. Lo is primarily responsible for providing independent advice on the operations and management of our Group.

Dr. Lo has served as an independent non-executive Director in (1) Television Broadcasts Limited (電視廣播有限公司), a company listed on the Stock Exchange (stock code: 511) primarily engaged in the operation of television channels, since February 2015; (2) CSI Properties Limited (資本策略地產有限公司), a company listed on the Stock Exchange (stock code: 497) primarily engaged in the property investment and development business, since April 2014; (3) OCI International Holdings Limited (東建國際控股有限公司), a company listed on the Stock Exchange (stock code: 329) primarily engaged in the investment industry, since July 2021; (4) Regencell

Bioscience Holdings Ltd., a company listed on the NASDAQ (stock code: RGC) primarily engaged in the Chinese medicine biotechnology industry, since December 2021, (5) CWT International Limited, a company listed on the Stock Exchange (stock code: 521) since June 2025; and (6) NetDragon Websoft Holdings Limited (網龍網絡控股有限公司), a company listed on the Stock Exchange (stock code: 777) since August 2025. Prior to that, Dr. Lo served as an independent non-executive director in the following companies listed on the Stock Exchange, including (1) Jingrui Holdings Limited (景瑞控股有限公司) (stock code: 1862), a company primarily engaged in property investment and development business, from October 2013 to December 2024; and (2) Oshidori International Holdings Limited (威華達控股有限公司) (stock code: 622), a company primarily engaged in the financial services business, from June 2021 to June 2023.

In addition, Dr. Lo currently serves as the governor of ISF Academy (弘立書院), the chairman of Charles K. Kao Foundation for Alzheimer's Disease (高錕慈善基金) and the chairman of Junior Achievement HK (青年成就計劃(香港)). Dr. Lo served as an executive director and vice president in China Unicom Limited, the managing director in Hong Kong Telecom IMS, the chief executive officer of Global Personal Banking, Hong Kong in Citibank HK, the vice chairman and managing director & chief financial officer in I.T Limited and the vice chairman in South China Media Group in the past, and he started his career as a management consultant in McKinsey & Company Inc.

Dr. Lo obtained a doctor of philosophy degree from the Cambridge University in the United Kingdom in March 1988.

Mr. Yang Mingyuan (楊明遠), aged 43, was appointed in June 2025 as our independent non-executive Director which will become effective upon the [**REDACTED**]. Mr. Yang is primarily responsible for providing independent advice on the operations and management of our Group.

Mr. Yang has been experienced in financial accounting. Since October 2025, Mr. Yang has served as the chief financial officer and board secretary in Affinity (Shanghai) Biopharmaceutical Co., Ltd. (亞飛(上海)生物醫藥科技股份有限公司), a company primarily engaged in the R&D of biopharmaceutical technology and products. Mr. Yang has served as a director, board secretary and the chief financial officer in Jiangsu Yahong Medtech Co., Ltd. (江蘇亞虹醫藥科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688176) which is primarily engaged in the research, development, production and sales of innovative drugs, since May 2020. Prior to that, from May 2018 to May 2020, Mr. Yang served as a deputy general manager of finance in Shuangquan Holdings. From May 2014 to May 2018, Mr. Yang worked with his last position being a business unit compliance director in Shanghai Novartis Trading Co., Ltd. (上海諾華貿易有限公司), a company which was engaged in the trading of medicine business. From December 2006 to April 2014, Mr. Yang worked with his last position being a manager in the Shanghai Branch of KPMG (畢馬威華振會計師事務所(特殊普通合夥)上海分所), an accounting firm providing professional services.

Mr. Yang obtained his master of business administration degree from Shanghai Jiaotong University (上海交通大學) in Shanghai, the PRC in March 2018.

Mr. Yang was accredited as a Certified Public Accountant by the Chinese Institute of Certified Public Accountants in June 2014. Mr. Yang was also certified as a Financial Risk Manager by the Global Association of Risk Professionals in April 2010. Mr. Yang is a Chartered Financial Analysis accredited by the CFA Institute. Therefore, Mr. Yang has the appropriate professional qualifications and accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules.

SENIOR MANAGEMENT

The following table sets forth information regarding the senior management members of our Company (excluding the executive Directors disclosed above):

Name	Age	Position	Date of joining our Group	Date of appointment as a senior management member	Responsibility	Relationship with other Directors and senior management
Mr. Xie Tonghai (謝同海). . . .	48	Financial controller and joint company secretary	March 31, 2021	March 31, 2021	Overall financial management of our Group	N/A
Ms. Zhang Dan (張丹)	53	Executive president	June 7, 2023	September 1, 2025	Management of daily operations of the medical institutions of our Group	N/A
Ms. Wu Gengyu (吳庚鈺) . . .	37	Investment and development director	June 13, 2018	June 13, 2018	Investment, and mergers and acquisitions matters of our Group	N/A

Ms. Bian Jiao (卞嬌), aged 37, our executive Director and chief executive officer. See "— Board of Directors — Executive Directors and non-executive Directors" for her biographical details.

Mr. Dong Lei (東磊), aged 45, is our executive Director and executive president. See "— Board of Directors — Executive Directors and non-executive Directors" for his biographical details.

Mr. Xie Tonghai (謝同海), aged 48, is our financial controller and joint company secretary. Mr. Xie joined our Company in March 2021 as our Company's financial controller. Mr. Xie is primarily responsible for the overall financial management of our Group.

Prior to joining our Group, from August 2017 to October 2020, Mr. Xie served as a financial controller in Beijing Feelfing Culture Media Co., Ltd. (北京非凡影界文化傳媒股份有限公司), a company principally engaged in the media business. From September 2007 to July 2014, Mr. Xie worked with his last position being a manager in KPMG Huazhen (Special General Partnership), an accounting firm providing professional services.

Mr. Xie obtained a master's degree in applied finance from Macquarie University in Sydney, Australia in September 2016. Mr. Xie was certified as a Certified Public Accountant by the Beijing Institute of Certified Public Accountants in September 2014. Mr. Xie was also certified as a Certified Tax Agent by the Beijing Certified Tax Agents Association in May 2018. In addition, Mr. Xie was obtained the qualification of Senior Accountant (高級會計師) from the Beijing Human Resources and Social Securities Bureau (北京市人力資源和社會保障局) in September 2020. Mr. Xie was admitted as a fellow of the Association of Chartered Certified Accountants in November 2021.

Ms. Zhang Dan (張丹), aged 53, is our executive president, who was appointed as our executive president in September 2025. Ms. Zhang joined our Company in June 2023 as the director of quality control. Ms. Zhang is primarily responsible for the management of daily operations of our medical institutions.

Prior to joining our Company, from June 2014 to May 2023, Ms. Zhang worked successively as the chief physician of the emergency department and the chief physician of the infectious diseases department in Peking University Shougang Hospital (北京大學首鋼醫院).

Ms. Zhang obtained a bachelor's degree in clinical medicine from Chengde Medical University (承德醫學院) in July 1995. In addition, Ms. Zhang obtained a master's degree in internal medicine from Peking University (北京大學) in July 2010. Ms. Zhang obtained the professional title of Chief Physician (主任醫師) accredited by Beijing Senior Specialised Technique Titles Evaluation Committee (北京市高級專業技術職務評審委員會) in November 2018.

Ms. Wu Gengyu (吳庚鈺), aged 37, is our investment and development director. Ms. Wu has been our investment and development director since June 2018. Ms. Wu is primarily responsible for the investment, and mergers and acquisitions matters of our Group.

Prior to joining our Group, from September 2017 to May 2018, Ms. Wu served as the general manager in Zhongcai Huibang (Beijing) Investment Fund Management Co., Ltd. (中財匯邦(北京)基金管理有限公司), a company which was principally engaged in equity investment. From May 2017 to September 2017, Ms. Wu worked in China International Intellectech (Shenzhen) Co., Ltd. (深圳中智經濟技術合作有限公司), a company which was principally engaged in enterprise management advisory services. From September 2016 to April 2017, Ms. Wu worked in Shenzhen Jingcheng Zhibang Enterprise Management Consulting Co., Ltd. (深圳市精誠智幫企業管理諮詢有限公司), a company which was principally engaged in enterprise management advisory services. From January 2016 to July 2016, Ms. Wu worked in Shenzhen Echo Private Equity Fund Management Co., Ltd. (深圳君創私募股權基金管理有限公司), a company which was principally engaged in equity investment. From July 2013 to September 2015 and from November 2015 to December 2015, Ms. Wu worked in Shenzhen Branch of Ping An Bank Co., Ltd. (平安銀行股份有限公司深圳分行), a Chinese joint-stock commercial bank.

Ms. Wu obtained a master of business administration in finance from the Chinese University of Hong Kong, Shenzhen (香港中文大學(深圳)) in November 2018.

Save as disclosed above, each of our Directors and senior management members confirms with respect to himself or herself that he or she (i) had no other relationship with any Director, senior management or substantial Shareholder of our Company as at the Latest Practicable Date; (ii) did not hold any other directorships in the three years prior to the Latest Practicable Date in any public companies of which the securities are listed on any stock exchange in Hong Kong and/or overseas; and (iii) there are no other matters concerning our Directors' appointment that need to be brought to the attention of our Shareholders and the Stock Exchange or shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

JOINT COMPANY SECRETARIES

Mr. Xie Tonghai (謝同海), aged 48, is our financial controller and joint company secretary. See "– Senior Management" for his biographical details.

Ms. Pun Ka Ying (盤嘉盈), is a joint company secretary of our Company.

Ms. Pun is a senior manager of company secretarial services of Tricor Services Limited, and she possesses more than 15 years of experience in the company secretary profession. She is familiar with the Listing Rules, the Companies Ordinance as well as compliance work for offshore companies. She has been providing corporate secretarial, corporate governance and compliance services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Pun is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

BOARD COMMITTEES

The Company [has established] three committees under the Board, namely the Audit Committee, the Remuneration Committee and the Nomination Committee.

Audit Committee

The Audit Committee consists of three Directors, namely Mr. Yang Mingyuan, Dr. Ma Weihua and Dr. Lo Wing Yan William, with Mr. Yang Mingyuan currently serving as the chairman. Mr. Yang Mingyuan has the appropriate professional qualification and experiences as required under Rules 3.10(2) and 3.21 of the Listing Rules. The Audit Committee is mainly responsible for reviewing and overseeing the financial reporting procedure, risk management and internal control system of our Group and have with terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

Remuneration Committee

The Remuneration Committee consists of three Directors, namely Dr. Ma Weihua, Mr. Wang Weibin and Dr. Lo Wing Yan William, with Dr. Ma Weihua currently serving as the chairman. The Remuneration Committee is mainly responsible for evaluating the remuneration polices for

Directors and senior management of our Group and making recommendations thereon to the Board of Directors and have with terms of reference in compliance with paragraph E.1 of part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

Nomination Committee

The Nomination Committee consists of five Directors, namely Mr. Wang Weibin, Ms. Bian Jiao, Dr. Ma Weihua, Mr. Yang Mingyuan and Dr. Lo Wing Yan William, with Mr. Wang Weibin currently serving as the chairman. The Nomination Committee is mainly responsible for identifying, screening and recommending to the Board qualified candidates to serve as the Directors and senior management and monitoring the procedures for evaluating the performance of the Board and have with terms of reference in compliance with paragraph B.3 of part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

DIVERSITY POLICY OF THE BOARD OF DIRECTORS

The Board has adopted a board diversity policy (the "Board Diversity Policy") in order to enhance the effectiveness of our Board and to maintain high standard of corporate governance. The Board Diversity Policy sets out the criteria in selecting candidates to our Board o, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service. The ultimate decision will be based on merit and contribution that the selected candidates will bring to our Board.

Our Directors have a balanced mixed of knowledge and skills, including but not limited to overall business management, accounting, hospital management, human resources management, and law. The Board is of the view that our Board satisfies the Board Diversity Policy. In addition, our Board has a wide range of age, ranging from 36 years old to 77 years old. Two of our Directors are female. Our Board will also ensure that appropriate balance of gender diversity is achieved with reference to investors' expectation, and international and local recommended best practices.

The Nomination Committee is responsible for reviewing the diversity of the Board. After [**REDACTED**], the Nomination Committee will monitor and evaluate the implementation of the Board Diversity Policy from time to time to ensure its continued effectiveness. The Nomination Committee will also include in successive annual reports a summary of the Board Diversity Policy, including any measurable objectives set for implementing the Board Diversity Policy and the progress on achieving these objectives.

CORPORATE GOVERNANCE

Our Directors recognize the importance of good corporate governance in management and internal procedures so as to achieve effective accountability. Our Group is expected to comply with the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

The compensation and remuneration of our Directors and members of the senior management of our Company are determined by our Shareholders' meetings and our Board as appropriate in the form of salaries and bonuses. Our Company also reimburses them for expenses which are necessary and reasonably incurred in providing services to our Company or discharging their duties in relation to the operations of our Company. When reviewing and determining the specific remuneration packages for our Directors and members of the senior management of our Company, our Shareholders' meetings and our Board take into account factors such as salaries paid by comparable companies, time commitment, level of responsibilities, employment elsewhere in our Group and desirability of performance-based remuneration. As required by the relevant PRC laws and regulations, our Company also participates in various defined contribution plans organized by relevant provincial and municipal government authorities and welfare schemes for employees of our Company, including medical insurance, injury insurance, unemployment insurance, pension insurance, maternity insurance and housing provident fund.

Our Company offers executive Directors and senior management members, who are our employees, compensation in the form of salaries, bonuses, social security plans, housing provident fund plans and other benefits. Our independent non-executive Directors receive compensation based on their responsibilities in the form of allowance.

The aggregate amounts of remuneration paid or payable to the Directors for the years ended December 31, 2023, 2024 and 2025, were RMB0.5 million, RMB12.7 million and RMB15.2 million, respectively.

The aggregate amounts of remuneration (including fees, salaries, contribution to pension schemes, housing allowances, other allowances and benefits-in-kind and discretionary bonuses) paid or payable to the five highest paid individuals for the three years ended December 31, 2023, 2024 and 2025, were RMB3.5 million, and RMB12.7 million and RMB15.2 million, respectively.

It is estimated that remuneration equivalent to approximately RMB3.8 million in aggregate will be paid to the Directors by the Company for the year ending December 31, 2026, based on the arrangements in force as of the date of the document.

No remuneration was paid by the Company to the Directors or the five highest paid individuals as inducement to join or upon joining the Company or as a compensation for loss of office during the Track Record Period. Furthermore, none of the Directors had waived or agreed to waive any remuneration during the Track Record Period.

COMPLIANCE ADVISOR

The Company appointed Maxa Capital Limited as the compliance advisor pursuant to Rules 3A.19 of the Listing Rules, and the compliance advisor will advise our Company in the following circumstances.

(i) before the publication of any regulatory announcement, circular or financial report;

(ii) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues and share repurchases;

(iii) where the Company proposes to use the [**REDACTED**] of the [**REDACTED**] in a manner that is different from that detailed in this document or where our business activities, developments or results deviate from any forecasts, estimates or other information in this document; and

(iv) where the Stock Exchange makes an inquiry of the Company regarding unusual movements in the [**REDACTED**] or [**REDACTED**] volume of the Shares, the possible development of a false [**REDACTED**] in the Shares or any other matters.

The terms of the appointment of the compliance advisor will commence on the [**REDACTED**] and end on the date when the Company distributes the annual report of its financial results for the first full financial year commencing after the [**REDACTED**].

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that, as of the Latest Practicable Date, he or she did not have any interest in any business which competes, or is likely to compete, directly or indirectly, with our business, and requires disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on June 21, 2025; and (ii) understands his or her obligations as a director of a listed issuer under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors confirms (i) his/her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he/she has no past or present financial or other interest in the business of our Company or our subsidiaries or any connection with any core connected person of our Company under the Listing Rules as of the Latest Practicable Date; and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointment.